These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 9748169)
1. Cyclo-oxygenase 2 and breast cancer prevention. Non-steroidal anti-inflammatory agents are worth testing in breast cancer. Vainio H; Morgan G BMJ; 1998 Sep; 317(7162):828. PubMed ID: 9748169 [No Abstract] [Full Text] [Related]
2. [From the COX-concept (Cyclooxygenase-2) to clinical gain. Meloxicam sets the standard. World-wide interactive video conference, London, 26 September 1997]. Z Orthop Ihre Grenzgeb; 1997; 135(6 Suppl):1-4. PubMed ID: 9474258 [No Abstract] [Full Text] [Related]
4. Cyclo-oxygenase 2 inhibition in colorectal cancer therapy (Br J Surg 2003; 90: 1055-1067). Nash G Br J Surg; 2003 Dec; 90(12):1610. PubMed ID: 14648750 [No Abstract] [Full Text] [Related]
5. Use of a cyclo-oxygenase type-2-selective non-steroidal anti-inflammatory agent to prevent preterm delivery. Sawdy R; Slater D; Fisk N; Edmonds DK; Bennett P Lancet; 1997 Jul; 350(9073):265-6. PubMed ID: 9242810 [No Abstract] [Full Text] [Related]
6. 94th annual meeting of the American Association for Cancer Research Washington, DC--July 11-14, 2003. Lobert S Oncol Nurs Forum; 2003; 30(5):741-2. PubMed ID: 12966928 [No Abstract] [Full Text] [Related]
7. New evidence that NSAIDs reduce breast cancer risk. Oncology (Williston Park); 1997 Jul; 11(7):1046. PubMed ID: 9251123 [No Abstract] [Full Text] [Related]
8. New dogmas or old? Whittle BJ Gut; 2003 Sep; 52(9):1379-81. PubMed ID: 12912874 [TBL] [Abstract][Full Text] [Related]
9. COX-2: where are we in 2003?--distinction from NSAIDs becoming blurred. Day R Arthritis Res Ther; 2003; 5(3):116-9. PubMed ID: 12723976 [TBL] [Abstract][Full Text] [Related]
11. Correspondence re: Cotterchio et al., Nonsteroidal anti-inflammatory drug use and breast cancer risk. Cancer Epidemiol. Biomark. Prev., 10: 1213-1217, 2001. Mokbel K; Singh-Ranger G; Kirkpatrick K Cancer Epidemiol Biomarkers Prev; 2002 Jul; 11(7):674; author reply 674. PubMed ID: 12101118 [No Abstract] [Full Text] [Related]
12. Barrett's oesophagus with predominant intestinal metaplasia correlates with superficial cyclo-oxygenase-2 expression, increased proliferation and reduced apoptosis: changes that are partially reversed by non-steroidal anti-inflammatory drugs usage. Amano Y; Ishihara S; Kushiyama Y; Yuki T; Takahashi Y; Chinuki D; Miyake T; Miyaoka Y; Rumi MA; Ishimura N; Adachi K; Kinoshita Y Aliment Pharmacol Ther; 2004 Oct; 20(7):793-802. PubMed ID: 15379840 [TBL] [Abstract][Full Text] [Related]
13. Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. Mitchell JA; Warner TD Br J Pharmacol; 1999 Nov; 128(6):1121-32. PubMed ID: 10578123 [TBL] [Abstract][Full Text] [Related]
14. COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease. Willoughby DA; Moore AR; Colville-Nash PR Lancet; 2000 Feb; 355(9204):646-8. PubMed ID: 10696997 [TBL] [Abstract][Full Text] [Related]
15. [The use of non-steroidal anti inflammatory drugs (NSAIDs)--COX-2 inhibitors]. Tishler M; Langevetiz P; Nesher G Harefuah; 2002 Oct; 141(10):920-1. PubMed ID: 12420601 [No Abstract] [Full Text] [Related]
16. Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications--review and recommendations based on risk assessment. Chan FK; Graham DY Aliment Pharmacol Ther; 2004 May; 19(10):1051-61. PubMed ID: 15142194 [TBL] [Abstract][Full Text] [Related]